Literature DB >> 11290790

Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice.

E K Bikoff1, G Wutz, G A Kenty, C H Koonce, E J Robertson.   

Abstract

Current ideas about DM actions have been strongly influenced by studies of mutant strains expressing the H-2(b) haplotype. To evaluate DM contributions to class II activities in BALB/c mice, we generated a novel mutation at the DMa locus via embryonic stem cell technology. Unlike long-lived A(b)/class II-associated invariant chain-derived peptide (CLIP) complexes, mature A(d) and E(d) molecules are loosely occupied by class II-associated invariant chain-derived peptide and are SDS unstable. BALB/c DM mutants weakly express BP107 conformational epitopes and toxic shock syndrome toxin-1 superantigen-binding capabilities, consistent with partial occupancy by wild-type ligands. Near normal numbers of mature CD4(+) T cells fail to undergo superantigen-mediated negative selection, as judged by TCR Vbeta usage. Ag presentation assays reveal consistent differences for A(d)- and E(d)-restricted T cells. Indeed, the mutation leads to decreased peptide capture by A(d) molecules, and in striking contrast causes enhanced peptide loading by E(d) molecules. Thus, DM requirements differ for class II structural variants coexpressed under physiological conditions in the intact animal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290790     DOI: 10.4049/jimmunol.166.8.5087

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  An MHC class II restriction bias in CD4 T cell responses toward I-A is altered to I-E in DM-deficient mice.

Authors:  Paula R Menges; Scott A Jenks; Elizabeth K Bikoff; David R Friedmann; Zackery A G Knowlden; Andrea J Sant
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 2.  HLA-DM: arbiter conformationis.

Authors:  Andrea Ferrante
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

3.  Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence.

Authors:  Woelsung Yi; Nilufer P Seth; Tom Martillotti; Kai W Wucherpfennig; Derek B Sant'Angelo; Lisa K Denzin
Journal:  J Clin Invest       Date:  2010-04       Impact factor: 14.808

4.  Activation of Dendritic Cells Alters the Mechanism of MHC Class II Antigen Presentation to CD4 T Cells.

Authors:  Kyung-Jin Cho; Satoshi Ishido; Laurence C Eisenlohr; Paul A Roche
Journal:  J Immunol       Date:  2020-01-29       Impact factor: 5.422

Review 5.  Determinants of immunodominance for CD4 T cells.

Authors:  AeRyon Kim; Scheherazade Sadegh-Nasseri
Journal:  Curr Opin Immunol       Date:  2015-01-08       Impact factor: 7.486

6.  Protective response to Leishmania major in BALB/c mice requires antigen processing in the absence of DM.

Authors:  Tirumalai Kamala; Navreet K Nanda
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

7.  The nonconventional MHC class II molecule DM governs diabetes susceptibility in NOD mice.

Authors:  Marc A J Morgan; Pari S S Muller; Arne Mould; Stephen A Newland; Jennifer Nichols; Elizabeth J Robertson; Anne Cooke; Elizabeth K Bikoff
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

Review 8.  HLA-DO and Its Role in MHC Class II Antigen Presentation.

Authors:  Yuri O Poluektov; Aeryon Kim; Scheherazade Sadegh-Nasseri
Journal:  Front Immunol       Date:  2013-08-29       Impact factor: 7.561

Review 9.  A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells.

Authors:  Scheherazade Sadegh-Nasseri
Journal:  F1000Res       Date:  2016-06-09

10.  Endogenous antigen processing drives the primary CD4+ T cell response to influenza.

Authors:  Michael A Miller; Asha Purnima V Ganesan; Nancy Luckashenak; Mark Mendonca; Laurence C Eisenlohr
Journal:  Nat Med       Date:  2015-09-28       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.